Group A: Mild COPD

Characteristics:

• 0 or 1 moderate exacerbation not leading to hospital admission.
• mMRC 0-1 (mild dyspnea).
• CAT < 10 (mild symptoms).

Treatment:

• A bronchodilator (either LABA or LAMA). Single inhaler therapy is recommended for convenience and effectiveness.

Drug Orders:

1. Short-Acting Beta-Agonist (SABA):
   • Ventolin® (Salbutamol):
     • Dose: 100 mcg/puff, 2 puffs inhaled every 4-6 hours as needed for relief of acute symptoms.
     • Instructions: Use the inhaler as needed for relief of breathlessness.
2. Long-Acting Beta-Agonist (LABA):
   • Indacaterol (Onbrez® Breezhaler):
     • Dose: 150 mcg inhalation once daily.
     • Instructions: Inhale the contents of one capsule once daily using the Breezhaler device.
3. Long-Acting Muscarinic Antagonist (LAMA):
   • Tiotropium (Spiriva® HandiHaler or Respimat):
     • Dose: 18 mcg inhalation once daily (HandiHaler) or 5 mcg inhalation once daily (Respimat).
     • Instructions: Inhale the contents of one capsule once daily using the HandiHaler device or two puffs from the Respimat inhaler once daily.

Group B: Moderate COPD

Characteristics:

• 0 or 1 moderate exacerbation not leading to hospital admission.
• mMRC ≥ 2 (moderate to severe dyspnea).
• CAT ≥ 10 (moderate to severe symptoms).

Treatment:

• Dual therapy with LABA + LAMA. Single inhaler therapy is recommended for convenience and effectiveness.

Drug Orders:

1. LABA + LAMA Combination:
   • Glycopyrronium/Indacaterol (Ultibro® Breezhaler):
     • Dose: Glycopyrronium 50 mcg / Indacaterol 110 mcg inhalation once daily.
     • Instructions: Inhale the contents of one capsule once daily using the Breezhaler device.
   • Tiotropium/Olodaterol (Stiolto® Respimat):
     • Dose: Tiotropium 2.5 mcg / Olodaterol 2.5 mcg inhalation two puffs once daily.
     • Instructions: Inhale two puffs once daily using the Respimat device.
   • Umeclidinium/Vilanterol (Anoro® Ellipta):
     • Dose: Umeclidinium 62.5 mcg / Vilanterol 25 mcg inhalation once daily.
     • Instructions: Inhale one puff once daily using the Ellipta inhaler.

Group E: Severe COPD

Characteristics:

• ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization.

Treatment:

• Dual therapy with LABA + LAMA.
• Consider adding ICS if the blood eosinophil count is ≥ 300 cells/µL to reduce exacerbations.

Drug Orders:

1. LABA + LAMA Combination:
   • Glycopyrronium/Indacaterol (Ultibro® Breezhaler):
     • Dose: Glycopyrronium 50 mcg / Indacaterol 110 mcg inhalation once daily.
     • Instructions: Inhale the contents of one capsule once daily using the Breezhaler device.
   • Tiotropium/Olodaterol (Stiolto® Respimat):
     • Dose: Tiotropium 2.5 mcg / Olodaterol 2.5 mcg inhalation two puffs once daily.
     • Instructions: Inhale two puffs once daily using the Respimat device.
   • Umeclidinium/Vilanterol (Anoro® Ellipta):
     • Dose: Umeclidinium 62.5 mcg / Vilanterol 25 mcg inhalation once daily.
     • Instructions: Inhale one puff once daily using the Ellipta inhaler.
2. Adding ICS for High Eosinophils:
   • Triple Therapy (ICS + LABA + LAMA):
     • Fluticasone/Umeclidinium/Vilanterol (Trelegy® Ellipta):
       • Dose: Fluticasone 100 mcg / Umeclidinium 62.5 mcg / Vilanterol 25 mcg inhalation once daily.
       • Instructions: Inhale one puff once daily using the Ellipta inhaler.

Additional Options for Refractory COPD

• PDE-4 Inhibitors:
  • Roflumilast (Daxas®):
    • Dose: 500 mcg orally once daily.
    • Instructions: Take one tablet once daily, preferably in the morning with or without food.
• Methylxanthines:
  • Theophylline:
    • Dose: Extended-release formulation, dose adjusted based on therapeutic drug monitoring.
    • Instructions: As directed, based on therapeutic drug levels and individual response.

These drug orders are aligned with the GOLD 2023 guidelines for managing COPD in outpatient settings, providing a structured approach based on disease severity and patient characteristics.

Comparison of Seretide Accuhaler vs. Seretide Evohaler

Comparison of Berodual MDI vs. Berodual Forte

Revised COPD Treatment Plans Using Only Seretide and Berodual

Group A: Mild COPD

Characteristics:

• 0 or 1 moderate exacerbation not leading to hospital admission.
• mMRC 0-1 (mild dyspnea), CAT < 10 (mild symptoms).

Treatment:

• A bronchodilator (SABA or LABA) as needed.

Drug Orders:

• Berodual MDI: Ipratropium 20 mcg / Fenoterol 50 mcg per puff, 1-2 puffs, up to 4 times daily as needed for symptom relief.
• Seretide Evohaler 25/50 mcg: 2 puffs twice daily for ongoing symptom control.

Group B: Moderate COPD

Characteristics:

• 0 or 1 moderate exacerbation not leading to hospital admission.
• mMRC ≥ 2 (moderate to severe dyspnea), CAT ≥ 10 (moderate to severe symptoms).

Treatment:

• Dual therapy with LABA + LAMA.

Drug Orders:

• Seretide Accuhaler 50/250 mcg: 1 inhalation twice daily to manage symptoms and prevent exacerbations.
• Berodual MDI: 1-2 puffs, up to 4 times daily for symptom relief.

Group E: Severe COPD

Characteristics:

• ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization.

Treatment:

• LABA + LAMA, consider adding ICS if the blood eosinophil count is ≥ 300 cells/µL.

Drug Orders:

• Seretide Accuhaler 50/500 mcg: 1 inhalation twice daily for patients with severe COPD and high eosinophils.
• Berodual Forte: 1-2 puffs, up to 4 times daily for patients with more severe symptoms.

COPD Acute Exacerbation (COPD AE) Management in Inpatient Settings

1. Respiratory Support

• Oxygen Therapy:
  • Goal: Maintain SpO2 between 88-92%.
  • Rationale: Avoid over-oxygenation to prevent CO2 retention and hypercapnic respiratory failure, which can occur in COPD patients with chronic hypercapnia.
• Ventilatory Support:
  • Non-invasive Ventilation (NIV): Preferred initial approach for most COPD exacerbations if available. Benefits include reduced infection risk, easier weaning, and shorter hospital stays.
  • Invasive Mechanical Ventilation: Consider if NIV is unavailable or if the patient does not respond to NIV.

2. Pharmacological Treatment

• Bronchodilators:
  • SABA + Anticholinergic:
    • Berodual (Fenoterol + Ipratropium Bromide):
      • COVID-19 Era (Use MDI to reduce aerosol spread):
        • Order: Berodual MDI 2-4 puffs via spacer every 20 minutes for 3 doses.
      • Normal Era (Use Nebulizer):
        • Order: Berodual Forte 1 vial nebulized every 20 minutes for 3 doses.
      • Maintenance:
        • MDI: 4 puffs via spacer every 2-4 hours.
        • Nebulizer: Every 6 hours.
• Steroids:
  • Dexamethasone:
    • Order: Dexamethasone 8 mg IV stat (initial dose).
    • Maintenance: Switch to oral prednisolone as symptoms improve.
      • Prednisolone:
        • Order: Prednisolone 40 mg/day (8 tablets of 5 mg) for a total of 5 days, as per GOLD 2020.
      • Alternative (Thai Guideline): Prednisolone 30 mg/day (6 tablets of 5 mg) for 5 days.
• Antibiotics:
  • Indication: If there are signs of a respiratory infection (increased dyspnea, increased sputum purulence, increased sputum volume) or if the patient requires mechanical ventilation.
  • Options:
    • Azithromycin:
      • Order: Azithromycin 500 mg orally on day 1, followed by 250 mg orally once daily for days 2-5.
    • Alternative Regimen: Based on local resistance patterns; options include Amoxicillin-Clavulanate or Doxycycline.
  • Duration: 5-7 days.

3. Before Discharge (D/C):

• Optimize Controller Medications: Adjust long-term inhalers and medications based on the patient's current status.
• Smoking Cessation: Strongly advise patients to quit smoking if they are still smoking.
• Inhaler Technique: Reassess and ensure correct inhaler technique.
• Assess Need for Home Oxygen: Evaluate if the patient needs home oxygen therapy.
• Follow-Up: Schedule follow-up appointments as appropriate.
• Vaccinations: Recommend influenza and pneumococcal vaccinations if not already received.
• Avoid Triggers: Educate the patient on avoiding known triggers for COPD exacerbations.

Summary of Practical Points:

• Respiratory Failure: Consider intubation if severe.
• Bronchodilators: Use MDI or nebulizer based on the setting (COVID-19 considerations).
• Steroids: Start with IV dexamethasone, then switch to oral prednisolone.
• Antibiotics: Start if infection signs are present or if ventilatory support is needed.
• Monitor and Reassess: Before discharge, ensure all aspects of COPD management are optimized.

Definition and Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) is defined as a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities. These changes are usually caused by significant exposure to harmful particles or gases, most commonly from smoking. The diagnosis of COPD is confirmed by a post-bronchodilator FEV1/FVC ratio of less than 0.7, indicating that the airflow obstruction is not fully reversible. COPD also involves chronic inflammatory responses in the lungs and systemic effects.

Pathophysiological Changes in COPD:

• Chronic Inflammation: Persistent inflammation in the airways and lung parenchyma causes structural changes, airflow limitation, and mucus hypersecretion.
• Airflow Limitation: Narrowing of the small airways and destruction of alveoli results in emphysema and chronic bronchitis.
• Air Trapping and Hyperinflation: Loss of lung elastic recoil and small airway collapse during expiration lead to air trapping and hyperinflation, contributing to dyspnea.
• Gas Exchange Impairment: Destruction of alveolar walls reduces the surface area for gas exchange, potentially causing hypoxemia and hypercapnia.
• Systemic Effects: COPD can have systemic implications, including cardiovascular disease, muscle wasting, and osteoporosis.

Diagnosis of COPD

1. Clinical History and Risk Factors:
   • Symptoms: Persistent cough, sputum production, and progressive dyspnea are hallmark symptoms.
   • Risk Factors: The most significant risk factor is smoking. Other risk factors include occupational dusts, chemicals, indoor and outdoor air pollution, and genetic predispositions like alpha-1 antitrypsin deficiency.
2. Spirometry:
   • Essential Diagnostic Tool: Spirometry is the gold standard for diagnosing COPD and assessing its severity.
   • Key Measurements:
     • FEV1 (Forced Expiratory Volume in 1 second): Volume of air exhaled in the first second of a forceful breath.
     • FVC (Forced Vital Capacity): Total volume of air exhaled during a forceful breath.
     • FEV1/FVC Ratio: A post-bronchodilator FEV1/FVC ratio less than 0.70 confirms the presence of airflow limitation characteristic of COPD.
3. Assessment of Severity (Based on FEV1):
   • Mild (GOLD 1): FEV1 ≥ 80% predicted
   • Moderate (GOLD 2): 50% ≤ FEV1 < 80% predicted
   • Severe (GOLD 3): 30% ≤ FEV1 < 50% predicted
   • Very Severe (GOLD 4): FEV1 < 30% predicted
4. Additional Diagnostic Tools:
   • Imaging: Chest X-rays help exclude other conditions and detect complications like pneumothorax. High-Resolution CT (HRCT) can detail the extent of emphysema and bronchitis but is not routinely used.
   • Exclusion of Other Diagnoses: Rule out asthma, heart failure, bronchiectasis, and other respiratory conditions.
   • Symptom Assessment: Use of the Modified British Medical Research Council (mMRC) Dyspnea Scale and the COPD Assessment Test (CAT) to evaluate symptom severity and quality of life.

Updated Guidelines and Management Strategies

Latest Guidelines Overview:

• Thai CPG 2022 and COPD GOLD 2024 emphasize updated classifications and treatment pathways to improve patient outcomes.
• COPD Classification:
  • Thai CPG 2022: Groups patients into A, B, C, and D based on symptom severity (mMRC, CAT) and exacerbation history.
  • COPD GOLD 2023, 2024: Introduces a simplified classification (A, B, E) focused on symptoms and exacerbation risk.
• Initial Pharmacological Treatment:
  • Group A: Mild symptoms, low risk of exacerbations—recommend starting with a bronchodilator (LABA or LAMA).
  • Group B: Moderate symptoms, low exacerbation risk—dual bronchodilation (LABA + LAMA).
  • Group E: Severe airflow limitation or high exacerbation risk—consider dual therapy (LABA + LAMA), with the addition of ICS (Inhaled Corticosteroids) if the blood eosinophil count is ≥ 300 cells/µL.
• Use of Inhaled Corticosteroids (ICS):
  • Indications for ICS: Not recommended as monotherapy. ICS is considered for patients with frequent exacerbations and elevated eosinophil counts (≥ 300 cells/µL) or those with an asthma-COPD overlap (ACO).
• Non-Pharmacological Management:
  • Smoking Cessation: Critical for all patients; can include pharmacological support.
  • Physical Activity and Pulmonary Rehabilitation: Encouraged for improving lung function and quality of life.
  • Vaccinations: Annual flu vaccine, pneumococcal, COVID-19, and shingles vaccines as per guidelines.

Specific Recommendations Based on COPD GOLD 2024 Guidelines

1. Group A:
   • Characteristics: Patients with 0 or 1 moderate exacerbation not leading to hospital admission, mMRC 0-1, CAT < 10.
   • Treatment: A bronchodilator (LABA or LAMA). Single inhaler therapy is recommended as it may be more convenient and effective.
2. Group B:
   • Characteristics: Patients with 0 or 1 moderate exacerbation not leading to hospital admission, mMRC ≥ 2, CAT ≥ 10.
   • Treatment: Dual therapy with LABA + LAMA. Single inhaler therapy is recommended for convenience and effectiveness.
3. Group E:
   • Characteristics: Patients with ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization.
   • Treatment: Dual therapy with LABA + LAMA. Consider adding ICS if the blood eosinophil count is ≥ 300 cells/µL to reduce exacerbations.

Monitoring and Follow-Up

1. Regular Assessment:
   • Monitor symptoms using CAT and mMRC scores, and track exacerbation history.
   • Adjust treatment based on symptom control, exacerbation frequency, and patient preferences.
2. Treatment Adjustments:
   • Escalation: Step up therapy to dual or triple therapy if symptoms worsen or exacerbations occur.
   • De-escalation: Consider reducing ICS use if there are side effects or no clear benefit.
   • Alternative Therapies: Use PDE-4 inhibitors like Roflumilast for chronic bronchitis or macrolides for former smokers with frequent exacerbations.

Practical Points for Internal Medicine

• Confirm COPD Diagnosis with Spirometry: Essential for all suspected cases to confirm the presence of airflow limitation.
• Personalize Treatment Plans: Base decisions on symptom severity, exacerbation history, and patient characteristics (e.g., eosinophil count, presence of asthma).
• Educate Patients on Inhaler Technique and Adherence: Ensure patients understand proper use to maximize medication efficacy.
• Incorporate Both Pharmacological and Non-Pharmacological Approaches: Address both symptom management and lifestyle factors for comprehensive care.

Case Study: Clinical Application

Case Study 3: 72-Year-Old Female with COPD:

• History: Hypertension, progressive dyspnea on exertion, blood pressure 179/100 mmHg, spirometry confirms COPD (FEV1/FVC = 0.68).
• Management: Based on GOLD 2024 guidelines, initiate treatment with long-acting bronchodilators. Monitor response and adjust treatment as needed based on exacerbation history and symptom control.

COPD Acute Exacerbation

COPD Acute Exacerbation

The 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines a COPD exacerbation as an acute worsening of respiratory symptoms that typically occurs over a period of less than 14 days. A COPD exacerbation is characterized by:

• A change in the patient's baseline cough, dyspnea (shortness of breath), or sputum production.
• An acute onset of symptoms.
• An event that may necessitate a change in the patient's regular medication regimen.
• Not necessarily accompanied by wheezing.

This definition clarifies that while wheezing can be a symptom of an exacerbation, it is not required for the diagnosis. The emphasis is on monitoring changes in key respiratory symptoms to effectively identify and manage exacerbations.

Management Plan for COPD Acute Exacerbation

1. Bronchodilator Therapy

Medication: Berodual (a combination of Ipratropium bromide and Fenoterol hydrobromide)

Dosage:

• Initial: 1 nebulizer (nb) dose every 15 minutes for up to 3 doses, depending on the severity of the exacerbation.
• Maintenance: 1 nb dose every 6 hours or as needed, based on the patient’s response and symptom control.

Rationale: Bronchodilators help relieve bronchospasm, improve airflow, and reduce symptoms such as shortness of breath and cough.

2. Corticosteroid Therapy

Options: Dexamethasone or Hydrocortisone

Dosage:

• Dexamethasone: Typically 4-6 mg IV every 6-12 hours. The exact dose may vary based on patient-specific factors and the severity of the exacerbation.
  • Alternative regimen: 8 mg IV once daily
• Hydrocortisone: 100 mg IV initially, with subsequent doses determined by clinical response.

Shift in Therapy: After 7 days of intravenous corticosteroid therapy, switch to oral Prednisolone to prevent adrenal insufficiency. This approach helps taper off steroids safely while reducing potential side effects associated with prolonged systemic corticosteroid use.

Prednisolone Dosage:

• Standard regimen: 25-40 mg orally each morning for 5 days.
  • Alternative regimen: 5 mg tablets, 2 tablets taken orally three times a day (2x3) po pc after meals for 5 days.

Rationale: Corticosteroids reduce inflammation in the airways, shorten recovery time, and improve lung function. The switch to oral Prednisolone after initial IV therapy is intended to reduce the risk of adrenal suppression, which can occur with long-term steroid use.

Additional Considerations

• Oxygen Therapy: Maintain target oxygen saturation (SpO₂) between 88-92% using supplemental oxygen to prevent hypoxemia while avoiding hypercapnia.
• Antibiotic Therapy: Consider antibiotics if there are signs of bacterial infection, such as increased sputum purulence or volume, or fever. A typical regimen might include Azithromycin 500 mg orally on day 1, followed by 250 mg orally once daily for days 2-5.
• Non-invasive Ventilation (NIV): Recommended for patients with respiratory acidosis (pH < 7.35) or severe dyspnea with signs of respiratory muscle fatigue.
• Smoking Cessation: Strongly advise all patients to quit smoking to reduce the risk of future exacerbations and slow disease progression.
• Follow-Up and Vaccinations: Ensure follow-up care and vaccinations (e.g., influenza and pneumococcal vaccines) are up to date to prevent future exacerbations.

Indications for Endotracheal Intubation (ETT) in COPD Patients:

1. Severe Respiratory Acidosis:
   • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG) pH < 7.25: Indicates severe acidosis, typically due to hypercapnia (high CO2 levels) which the patient is unable to compensate for through increased respiratory effort.
2. Severe Hypercapnia:
   • Partial Pressure of Carbon Dioxide (PCO2) > 55 mmHg: This level indicates significant hypercapnia, suggesting that the patient's ventilatory capacity is overwhelmed, and they are unable to clear CO2 effectively.
3. Severe Hypoxemia:
   • Oxygen Saturation (SpO2) < 88% or Partial Pressure of Oxygen (PaO2) < 60 mmHg on supplemental oxygen: This criterion indicates inadequate oxygenation despite high-flow oxygen therapy, necessitating mechanical ventilation to improve gas exchange.
4. Respiratory Distress:
   • Respiratory Rate (RR) > 35 breaths per minute: Indicates severe respiratory distress and inability to maintain adequate ventilation, which may quickly lead to respiratory failure.
5. Decreased Level of Consciousness:
   • Glasgow Coma Scale (GCS) drop > 2 points from baseline or GCS < 8: A significant drop in GCS suggests impaired consciousness due to hypercapnia, hypoxemia, or other metabolic disturbances, indicating the need for airway protection and mechanical ventilation.